Trump’s Opioid Panel Wants More Treatment Options and Drug Courts

The commission put no dollar figure on how much it would cost to support its solutions

Join Our Community of Science Lovers!

(Reuters) - A panel convened by U.S. President Donald Trump to tackle the opioid crisis called on Wednesday for more treatment programs, tighter prescribing guidelines and additional drug courts to help reduce overdose deaths.

The commission, led by New Jersey Governor Chris Christie, said the recommendations would require funding by Congress but did not recommend an amount. Trump last week declared the opioid crisis a public health emergency.

Public health experts broadly welcomed the proposed measures.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


"This sounds to me like a very progressive and very needed move," said Professor Kosali Simon, a health economist at Indiana University, of the recommendations.

But Paul Hanly, a New York lawyer representing local governments in a legal battle against opioid makers, said recommendations, while laudable, would be "toothless" without substantial funding.

Opioids include prescription painkillers, heroin and fentanyl. More than 100 Americans die daily from overdoses, according to federal data.

The commission recommended a national media campaign to encourage opioid addicts to seek help. Only 10.6 percent of people who need treatment get it, the report noted.

The media campaign would encourage addicts to "stop being afraid or ashamed of seeking help when facing their addiction."

It urged expansion of drug courts, in which addicts convicted of non-violent offenses are diverted into programs that combine treatment with mandatory drug testing and court appearances.

The commission said drug courts, which are currently offered in just 44 percent of U.S. counties, should embrace medication-assisted treatment to improve outcomes.

The U.S. Food and Drug Administration last week announced plans to encourage wider use of substitute opioids such as methadone and buprenorphine, which do not induce a high and are used to help people through drug addiction recovery.

Still, Dr. Stefan Kertesz of the University of Alabama at Birmingham said communities often lack treatment facilities where drug courts can send addicts. And many drug courts charge fees that make them unaffordable for many.

"Drug courts often function as pay to play," Kertesz said. "Only people who can come up with money can escape a prison sentence."

The report recommended expanding the ranks of emergency responders allowed to administer naloxone to treat overdoses. It also encouraged stricter prescribing guidelines for physicians.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe